Premium
Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement
Author(s) -
AlAdra David P.,
Hammel Laura,
Roberts John,
Woodle E. Steve,
Levine Deborah,
Mandelbrot Didier,
Verna Elizabeth,
Locke Jayme,
D'Cunha Jonathan,
Farr Maryjane,
Sawinski Deirdre,
Agarwal Piyush K.,
Plichta Jennifer,
Pruthi Sandhya,
Farr Deborah,
Carvajal Richard,
Walker John,
Zwald Fiona,
Habermann Thomas,
Gertz Morie,
Bierman Philip,
Dizon Don S.,
Langstraat Carrie,
AlQaoud Talal,
Eggener Scott,
Richgels John P.,
Chang George J.,
Geltzeiler Cristina,
Sapisochin Gonzalo,
Ricciardi Rocco,
Krupnick Alexander S.,
Kennedy Cassie,
Mohindra Nisha,
Foley David P.,
Watt Kymberly D.
Publication year - 2021
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.16318
Subject(s) - medicine , malignancy , immunosuppression , transplantation , intensive care medicine , cancer , disease , candidacy , oncology , politics , political science , law
Patients undergoing evaluation for solid organ transplantation (SOT) often have a history of malignancy. Although the cancer has been treated in these patients, the benefits of transplantation need to be balanced against the risk of tumor recurrence, especially in the setting of immunosuppression. Prior guidelines of when to transplant patients with a prior treated malignancy do not take in to account current staging, disease biology, or advances in cancer treatments. To develop contemporary recommendations, the American Society of Transplantation held a consensus workshop to perform a comprehensive review of current literature regarding cancer therapies, cancer stage‐specific prognosis, the kinetics of cancer recurrence, and the limited data on the effects of immunosuppression on cancer‐specific outcomes. This document contains prognosis based on contemporary treatment and transplant recommendations for breast, colorectal, anal, urological, gynecological, and nonsmall cell lung cancers. This conference and consensus documents aim to provide recommendations to assist in the evaluation of patients for SOT given a history of a pretransplant malignancy.